Asymchem Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Asymchem Inc. - overview
Established
1998
Location
Tianjin, -, China
Primary Industry
Pharmaceuticals
About
Founded in 1998 and based in Tianjin, China, Asymchem Inc. operates as a pharmaceutical company that focuses on the development and production of new drugs and APIs. The company has 8 R&D and production bases, as well as more than 20 R&D, production, and sales subsidiaries and offices located in Tianjin, Jilin, Shanghai, and other places. It cooperated with global pharmaceutical companies such as Pfizer, Merck, AbbVie, etc.
Hao Hong, the chairman and CEO of the company, graduated from the Chinese Academy of Medical Sciences and is also a visiting professor at Sichuan University. In December 2021, the company was listed on the Hong Kong Stock Exchange. In February 2020, Asymchem Laboratories raised a PIPE funding for CNY 2. 31 billion.
The company is mainly engaged in the research and development of new drugs and drug APIs. It combines molecular biology technology, fermentation technology, and process development technology to provide users with carbapenem drugs, cGMP APIs and other products. The products can be used to treat major diseases such as antiviral, anticancer, cardiovascular and cerebrovascular diseases, and diabetes. The company generates revenue by providing new drugs and APIs.
Current Investors
Tianjin Venture Capital, CoStone Capital, Wings Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.asymchem.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.